EP2170288A2 - Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci - Google Patents

Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci

Info

Publication number
EP2170288A2
EP2170288A2 EP08716523A EP08716523A EP2170288A2 EP 2170288 A2 EP2170288 A2 EP 2170288A2 EP 08716523 A EP08716523 A EP 08716523A EP 08716523 A EP08716523 A EP 08716523A EP 2170288 A2 EP2170288 A2 EP 2170288A2
Authority
EP
European Patent Office
Prior art keywords
pellets
particles
pharmaceutical
droplets
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08716523A
Other languages
German (de)
English (en)
Inventor
Burkhard Schlütermann
Frédéric GERBER
Michael Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADD Advanced Drug Delivery Technologies AG
Original Assignee
ADD Advanced Drug Delivery Technologies AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADD Advanced Drug Delivery Technologies AG filed Critical ADD Advanced Drug Delivery Technologies AG
Publication of EP2170288A2 publication Critical patent/EP2170288A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the invention relates to pellets containing a pharmaceutical substance with a breaking strength of more than 0.001 Newton, processes for their preparation and pharmaceutical preparations based on such pellets.
  • pellets for example, there are pharmaceutical pellets containing a so-called starter core based on a pharmaceutical excipient, which is coated with a layer containing a pharmaceutical agent.
  • starter cores for example, sucrose crystals or spherical bodies from an excipient combination of sucrose and starch have been proposed for these purposes.
  • particles based on microcrystalline cellulose there are particles based on microcrystalline cellulose.
  • spherical, particularly rapidly disintegrating bodies can be produced by special aggregation processes in the fluidized bed, which may contain, among other things, water-soluble carbohydrates as the main component.
  • a low water content and / or a lower water absorption capacity of such pellets can bring about improved process and stability behavior in the case of chemically labile or unstable active substances.
  • pharmaceutical excipients which are tolerated and are accepted by diabetics should increasingly be used.
  • the present invention is now intended to provide pellets which can be advantageously used for the production of pharmaceutical preparations.
  • pellets are to be provided which have a high mechanical strength. Furthermore, pellets are to be provided which are water-soluble and / or less hygroscopic.
  • pellets according to the invention are spherical as possible over a broad particle size range.
  • the pellets obtained should also be suitable in particular for further processing into oral administration forms, in particular those with a modified release profile.
  • the products produced are intended to permit a distribution of a pharmaceutical active substance to many subunits, which is advantageous from a bio-pharmaceutical point of view, in particular for modified-release preparations, since products based on this formulation concept show a low variability of the pharmacokinetic parameters.
  • the present invention is also intended to provide an oral pharmaceutical preparation which offers improved conditions for a controlled and robust further processing, in particular the application of coatings.
  • the invention therefore relates to a process for the preparation of pellets containing a pharmaceutical substance, preferably having a breaking strength of more than 0.001 Newton and in particular more than 0.05 Newton (hereinafter also abbreviated as "N"), comprising the steps:
  • the invention furthermore relates to pellets which contain a pharmaceutical substance and which preferably have a breaking strength of more than 0.001 Newton and in particular more than 0.05 Newton.
  • pharmaceutical substance is intended to designate drugs, pharmaceutical excipients and mixtures of such components.
  • the pharmaceutical substance contains a pharmaceutical excipient or mixtures of pharmaceutical excipients, in particular it consists thereof.
  • a pharmaceutical excipient or mixtures of pharmaceutical excipients in particular it consists thereof.
  • auxiliaries are, for example, binders, fillers and / or disintegrants.
  • composition It is preferably a water-soluble and / or non-hygroscopic pharmaceutical excipient.
  • preferred adjuvants are sucrose-free.
  • water-soluble a water solubility of more than 50 mg per liter at 20 0 C is understood to mean, preferably of more than 200 mg per liter at 20 ° C.
  • a substance is classified as "non-hygroscopic" if it does not absorb more than 10% by weight, in particular not more than 5%, of water when stored for 24 hours at a relative humidity of 50% at a temperature of 20 ° C.
  • auxiliaries are mono-, di- or polysaccharides and / or sugar alcohols, for example arabinose, ribose, xylose, glucose, mannose, galactose, fructose, lactose, maltose, trehalose, isomalt, inulin, mannitol, sorbitol, xylitol, maltitol, Erythritol and mixtures thereof.
  • sugar alcohols for example arabinose, ribose, xylose, glucose, mannose, galactose, fructose, lactose, maltose, trehalose, isomalt, inulin, mannitol, sorbitol, xylitol, maltitol, Erythritol and mixtures thereof.
  • mannitol is used as a pharmaceutical excipient.
  • the pellets according to the invention preferably contain the adjuvants listed above, in particular mannitol, in an amount of more than 50 to 100%, in particular from 80 to 100%.
  • the pellets consist essentially of the pharmaceutical excipient, especially of mannitol.
  • the pharmaceutical substance contains a pharmaceutical active substance.
  • a pharmaceutical active substance any drug that is solid at room temperature is possible.
  • the drug is not enzymes or ibuprofen.
  • the pellets according to the invention which contain a pharmaceutical excipient, are in a preferred embodiment so-called starter pellets, also known in English as “starter spheres.”
  • the starter pellets are also referred to as "cores.”
  • the cores essentially consist of Nuclei containing mannitol, or preferably consisting essentially of the pharmaceutical excipient mannitol, are referred to as mannitol nuclei
  • the starter pellets are usually coated with a drug-containing layer, In particular, starter pellets containing mannitol are preferred.
  • the pellets according to the invention are preferably spherical.
  • a particle is referred to as spherical when the length-to-width ratio (that is, the ratio of the length (largest dimension) of the particle divided by the width (smallest dimension) at an angle of 90 ° with respect to the length is determined) is less than about 1.4.
  • the length-to-width ratio of a spherical particle is less than about 1.3, more preferably less than about 1.2, even more preferably less than about 1.1, and most preferably less than about 1.05.
  • the particles are also characterized by their size.
  • the particle size distribution can be determined by sieve analysis. Unless otherwise stated, the particle size refers to the weight average.
  • the weight average particle diameter (D 50 ) is from 0.1 to 3 mm, more preferably from 0.15 to 1 mm. Depending on the intended use, weight-average particle diameters of, for example, 150 to 350 ⁇ m or 300 to 500 ⁇ m may be preferred.
  • the pellets according to the invention preferably have a narrow particle size distribution.
  • the particle size distribution is characterized by the ratio Dio / D 9O .
  • the ratio is preferably 0.4 to 1, more preferably 0.5 to 1, in particular 0.6 to 1.
  • Dio is the particle size at which 10% of the particles are smaller than this particle size
  • D 50 the particle size at which 50% of the particles are smaller than this particle size
  • D 90 the particle size at which 90% of the particles are smaller as this particle size.
  • the pellets of the invention may also have a preferred bulk density of from 0.5 to 1 g / ml, more preferably from 0.6 to 0.8 g / ml.
  • the pellets according to the invention preferably have a breaking strength of more than 0.001 N. More preferably, the pellets of the present invention have a breaking strength of greater than 0.005N, 0.01N, 0.05N, 0.1N, 0.15N, 0.2N, 0.25N, 0.3N, 0 , 35 N 1 0.4 N, 0.45 N, 0.5 N, 0.55 N, 0.6 N, 0.65 N, 0.7 N, 0.75 N, 0.8 N, 0 , 85 N, 0.9 N, 0.95 N, 1 N, 1, 5 N, 2 N, 2.5 N, 3 N, 3.5 N, 4 N, 4.5 N or alternatively 5 N on , Usually, the breaking strength is not more than 25 N or alternatively 10 N. In a preferred embodiment, the pellets have a breaking strength of 0.05 N to 10 N. The breaking strength is determined as follows:
  • the fracture strength of the spherical samples is measured on individual samples by uniaxial vertical loading between two horizontal jaws with plane-parallel surfaces.
  • the two jaws are made from pieces of a commercial (IOO) silicon wafer. Breaking strength is measured by recording a controlled force-displacement curve with a resolution of 2 mN in the range of 0 to 25 N.
  • the sample is placed on the lower jaw, after which the upper jaw is progressively lowered.
  • the force-displacement curve shows a first kink at the first contact of the sample with the upper jaw and reflects in the first section the alignment of the possibly not perfectly spherical sample between the two jaws. From this point, the elastic response of the sample is measured for the time being.
  • breaking strength here in units of N, "Newton"
  • the breaking strength may depend on the average particle diameter.
  • the quotient of breaking strength to weight average particle diameter is 0.005 to 10 [N / mm], more preferably 0.05 to 5 [N / mm], especially 0.5 to 3 [N / mm].
  • the invention also includes any combination of the embodiments described above.
  • the subject of the present invention is also a product comprising a plurality of particles.
  • a product comprises a collective of particles, typically 50 or more, preferably 100 or more particles.
  • a product according to the invention predominantly comprises particles which fulfill the particle criteria according to the invention.
  • at least 90%, in particular at least 95% and most preferably at least 98% of the particles have the properties described above with regard to breaking strength, weight-average particle diameter and length-width ratio.
  • pellets can be produced by the method of the present invention. As already explained, it has been found according to the invention that it is possible to produce spherical particles from individual droplets of a dispersion.
  • the particles preferably have a compact construction. Furthermore, it is preferred if the particles have a homogeneous surface structure (surface texture).
  • the process gas jet is essential for mass transport as well as for heat transport.
  • the process according to the invention comprises stages (a) to (d).
  • step (a) of the method according to the invention a solution or dispersion of a pharmaceutical substance is provided.
  • the pharmaceutical substance is provided by dissolving or dispersing in a solvent as a solution or dispersion.
  • pharmaceutical excipients are dissolved or dispersed, more preferably the aforementioned saccharides and / or sugar alcohols; especially mannitol.
  • dispersion is to be understood broadly in the context of this invention, which includes solid / liquid and liquid / phase systems, that is to say the term dispersion encompasses suspensions and emulsions.
  • the dispersant used for solutions, emulsions or suspensions is preferably water.
  • organic solvents or mixtures of two or more organic solvents as dispersants.
  • suitable organic solvents are alcohols, esters or chlorinated solvents such as methylene chloride.
  • mixtures of water with organic solvents are possible. Examples are water / alcohol or water / ethyl acetate. Preferably, water is used as the sole solvent.
  • step (b) of the process according to the invention droplets are generated by spraying the solution or dispersion into a process space.
  • the solution or dispersion is usually sprayed in at elevated temperature.
  • the temperature depends on the nature of the substance to be processed.
  • the Einsprühtemperatur should be at least 40 0 C below the melting temperature of the pharmaceutical substance.
  • the solution or dispersion at a temperature of 10 to 150 0 C, especially sprayed from 30 to 120 0 C, in particular from 60 to 100 0 C.
  • a spray rate of from 20 to 200, in particular from 30 to 50 g / min is used.
  • step (c) of the process according to the invention repeated passing of solid particles on sprayed-in droplets in the process space takes place with the aid of a preferably defined process gas jet.
  • a process gas jet is used to repeatedly pass solid particles past sprayed droplets.
  • the process gas may be, for example, air or an inert gas, such as nitrogen, carbon dioxide or a noble gas.
  • the process gas jet at a temperature between 10 0 C and 150 0 C, preferably from 60 ° to 110 0 C.
  • jet layer is understood to mean that the completely fluidized solid particles are in a temporally stable, closed solid flow.
  • the jet layer is generated by means of the defined process gas jet.
  • three fluidization states or zones are to be distinguished.
  • the acceleration of the solid particles takes place under the action of the defined process gas jet, wherein the particles in this zone move in the direction of flow of the process gas jet.
  • the process gas jet is guided vertically upwards. Accordingly, in the ejection zone of the jet layer, there is a vertically upwardly directed flow.
  • the particles change their direction of flow. There is one Cross flow before.
  • the particles enter a third zone or return zone. There, the particles then have an oppositely directed movement, until they finally return to the influence of the defined guided gas flow and are carried along again in the first zone. In the return zone, the particles typically move under the influence of gravity.
  • the spraying of the dispersion can be carried out by two-fluid and multi-fluid nozzles. Furthermore, it is possible to effect the spraying by pressure nozzles. Alternatively, dripping may be accomplished by rotary atomizers, jet cutters, ultrasonic drippers, and other devices known to those skilled in the art.
  • solid-particle nuclei by injecting droplets of a solution or dispersion into the process space and solidifying these droplets, it is possible to form solid-particle nuclei, which are then brought into contact with further droplets to form particles of the desired size.
  • solid particles may be supplied from outside in the process. For example, too small particles taken from the process can be returned to the process space as seed material. Likewise, too large particles removed from the process or agglomerates of particles may be crushed by any size reduction unit and returned to the process space as seed material.
  • step (d) of the process the particles formed are taken from the process space as a function of the particle size.
  • the material discharge of the finished product from the process space or material transport into a further downstream process space can take place in the region of the transition of the crossflow to the downward solids flow.
  • the particles discharged from the process space are not classified.
  • the particles discharged from the process space are classified by one or more viewing devices.
  • the method according to the invention can be carried out, for example, with the aid of a device as described in DE 103 22 062 A1 (zigzag sifter).
  • zigzag sifter The content of this application is incorporated herein by reference.
  • the method according to the invention is carried out using a device as shown in the attached Figure 1. This will be explained in detail below.
  • the amount of process gas 10 (usually heated air) required for solidifying the particles to be produced is fed to a supply air chamber 17 with a rectangular cross-section 9 and limiting side walls 5.
  • the process gas 10 is distributed and enters via stomata 1 in the process chamber 8 in the form of gas jets 2.
  • the process gas stream which preferably enters the gap 1 horizontally, is preferably deflected upwards into the process space 8 by the deflecting part 3 and flows into the apparatus as a kind of free jet.
  • the apparatus cross-section can optionally increase in the expansion zone 14, so that the speed of the process gas flow steadily decreases towards the top.
  • the gas exits the apparatus as waste gas 11 above the expansion zone 14 via the exhaust air part 19 into which optionally a dedusting system (for example filter cartridges or textile filter elements) can be integrated.
  • a dedusting system for example filter cartridges or textile filter elements
  • one or more spray nozzles 7 are arranged, which spray in the same direction upward to the process gas jet and serve to introduce the dispersion. Due to the high particle loading in the core zone 22 results in the Bedüsungszone 22 very advantageous conditions for the heat and mass transfer. Furthermore, it is achieved that the dispersion deposits as far as possible on the particles and thus they are wetted uniformly on the particle surfaces. The uniform wetting with simultaneous high solids circulation between the spray area and return zone 24 causes a very uniform liquid film is formed. The solidification process solidifies the dispersion and the solid remains on the particle surface.
  • the process gas can discharge part of the particles as well as fines and dusts as solids-laden exhaust air 20 out of the process chamber 8.
  • the filter system optionally integrated in the exhaust air part 19 or dedusting plants downstream of the apparatus can be used.
  • compressed air pulses 18 can be used to return the retained particles as separated solid 21 into the process space 8.
  • the dust return is facilitated by the fact that the upward process gas flow is essentially localized and thus the be returned attributable particles outside the gas jet safely. Due to the suction effect in the vicinity of the gas inlet gap 1, this mechanism is additionally promoted. Alternatively, particles separated from the exhaust air can be returned to the process space 8.
  • 29 different feeders 26 may be arranged in the lower region of the inclined side walls.
  • the fine particles Due to the high speed of the process gas jet in the vicinity of the gas inlet gap 1, the fine particles are sucked and fed to the Bedüsungszone 22, where they are wetted with dispersion and participate in the growth process.
  • Optionally built-in baffles 16 support the gas jet, enhance the suction effect and improve the supply of solids in the Bedüsungszone 22 inside. Possibly occurring agglomeration effects are minimized, since in the spraying area very high flow velocities and thus higher separation forces occur than in fluidized beds. As a result, particles are separated and grow into granules of spherical shape.
  • the flow profile of the process gas in the process chamber 8 furthermore causes fine particles which are returned from the optionally integrated filter system into the process space not to fall back into the spraying zone 22. As a result, the adhesion of fine particles and consequent agglomeration processes is prevented.
  • the apparatus can optionally be equipped with different feed systems 13 for solids.
  • particles can be supplied to the process, which can be obtained by comminution of, for example, (too large) granules or / and consist of too small granules. These particles then serve as granulation nuclei or as starter filling to shorten the commissioning time.
  • additives in solid form can be introduced into the process, which are to be embedded in the granules.
  • the apparatus can be provided with discharge elements 4 in order to be able to remove particles from the process space 8. This can be done for example by a Overflow or by a volumetric discharge (eg a rotary valve) or by a gravity funnel (eg, a zig-zag sifter acted upon with visual gas or a riser sight).
  • mechanical units 27 may be mounted in the process space 8, but preferably in the area of the return zone 24, on the inclined walls to produce by comminution sufficient fines as nuclei for the granulation process.
  • the return zone 24 can optionally be used for positioning of heaters or other heat transfer devices 28.
  • the apparatus wall may be double-walled in order to use it, for example, using liquid or gaseous heat carriers for heating or cooling the walls.
  • optimum surface temperatures can be adjusted, for example, to avoid product deposits.
  • spray nozzles 6 can optionally be arranged, which preferably spray downwards but also partly upwards.
  • the liquid formulation can be injected in order to produce, for example by spray-drying / spray hardening in the apparatus granulation.
  • additives or other components in liquid form can be sprayed over some of the spraying devices 6 and 7 and thus homogeneously embedded in the granule structure.
  • the spray nozzles 7 pass through the temperature-charged supply air chamber 17, optionally the liquid-carrying parts can be provided with insulation or different cooling or heating systems 12 in order to prevent damage to the liquid formulation.
  • Another advantage of the process according to the invention is the very simple structure to call, the high reliability and
  • the pellets produced by the process according to the invention are preferably inert, non-hygroscopic and spherical and have a smooth surface. They preferably have a high mechanical strength, a high density and low abrasion. They have a narrow particle distribution, wherein the average particle diameter can be adjusted as desired. In particular, they are suitable as starter pellets.
  • the pellets of the present invention may be treated with a drug-containing dispersion for the purpose of drug screening, i. to build up a drug layer to be sprayed in the fluidized bed.
  • the active ingredient is applied in dissolved or suspended form to the pellet of the invention.
  • Suitable solvents and suspending agents are water or alcohols such as methanol, ethanol or isopropanol or ketones such as acetone and mixtures of water and the organic solvents just described. Binders, release agents, stabilizers or other auxiliaries can be added to the dispersion medium described.
  • a functional coating for stabilization, taste masking or modification of the release properties can be applied.
  • enteric-coated films that modulate drug release i. delaying layers or retarding coatings applied to the pellets.
  • the pellet coated in this way may contain an outer separating layer or an outer phase.
  • pellets coated with active ingredient as described above are, in a preferred embodiment, pellets containing mannitol, and in particular pellets consisting essentially of mannitol.
  • the active substances are preferably chemically labile or unstable and moisture-sensitive pharmaceutical active substances, such as, for example, Duloxetine or a pharmaceutically acceptable salt thereof, such as duloxetine hydrochloride, or agents from the group of proton pump inhibitors, such as e.g. Pantoprazole, esomeprazole, omeprazole, lansoprazole, rabeprazole and their salts.
  • pellets which have a mannitol core and a drug layer in which the active ingredient is duloxetine or a pharmaceutically acceptable salt thereof, preferably duloxetine hydrochloride.
  • a pellet containing a pharmaceutical substance wherein the pellets have a breaking strength greater than 0.001 Newton.
  • Pellets according to any one of items 1 to 5 comprising a water-soluble and / or non-hygroscopic and sucrose-free pharmaceutical excipient.
  • Pellets according to any one of items 1 to 9 constructed from a mannitol nucleus and thereon a layer containing a pharmaceutically active substance.
  • step (d) removing particles from the process space as a function of the particle size. 12. The method according to item 11, wherein in step (b) a solution or dispersion at a temperature of 60 to 100 0 C is sprayed.
  • pellets as defined in any one of items 1 to 10 or 25 for the manufacture of a pharmaceutical dosage form, in particular for the production of a tablet, a capsule or a sachet.
  • a mannitol solution having a temperature of 90 ° C.-100 ° C. was sprayed into an apparatus characterized by the structure described above.
  • the supply of at about 75 0 C. preheated process air flow of about 100 m 3 / h was carried out via 2 longitudinally extending through the apparatus gas supply column.
  • the dispersion was sprayed into the process air stream at a barometric pressure of 2.3 bar via a two-fluid nozzle, sprayed vertically with compressed air, into the process air stream.
  • the process room contained about 500 g of mannitol powder.
  • the sifter Due to the pressure setting, the sifter mainly supplied material with a grain fraction between 160 ⁇ m and 315 ⁇ m.
  • the thus isolated pellets had a bulk density of about 0.7 g / ml.
  • the mannitol pellets were very round, of uniform grain distribution, very hard and had a smooth and shiny surface.
  • a mannitol solution having a temperature of 70 - sprayed into an apparatus 80 0 C, which is characterized by the above-described structure.
  • the supply of preheated to about 75 0 C process air flow of about 100 m 3 / h was carried out over 2 longitudinally extending through the apparatus gas supply column.
  • the dispersion was over a pressurized, vertically spraying two-fluid nozzle sprayed into the process air jet at an air pressure of 2.3 bar.
  • the process room contained about 500 g of mannitol powder.
  • the sifter Due to the pressure setting, the sifter mainly supplied material with a grain fraction between 315 ⁇ m and 500 ⁇ m.
  • the thus isolated pellets had a bulk density of about 0.7 g / ml.
  • the mannitol pellets were smooth, round and hard.
  • Duloxetine hydrochloride is completely dissolved in a 50:50 w / w mixture of ethanol and water (11.25% w / w solid). Methocel E6 LV is added to the solution so prepared (15.00% w / w total solids).
  • This solution is sprayed onto mannitol pellets with a grain size of 315-500 ⁇ m (75% increase in weight).
  • the mannitol pellets are fluidized in a fluidized bed apparatus of appropriate size (eg, smooth GPCG 1) with sausage insert and subsequently sprayed with the active ingredient solution.
  • the solution is sprayed with an air pressure of 2.0 bar.
  • the process room contains about 400 g of mannitol pellets.
  • the production of suitable Mannitol pellets are described in the above examples. The process conditions are listed below:
  • duloxetine hydrochloride-containing pellets containing mannitol as a starter core are chemically more stable to duloxetine hydrochloride-containing pellets containing a starter core of microcrystalline cellulose of comparable particle size.
  • Duloxetine hydrochloride-containing pellets with microcrystalline cellulose as the starting material were prepared under the same conditions as described above. The chemical stability of the two samples immediately after preparation was investigated by HPLC. The table below compares the chemical stability of the various duloxetine-hydrochlohd lots. The analysis method is briefly explained below.
  • HPLC instrument Rapid Resulotion System 1200 Series from Agilent Technologies
  • a weighed amount of standard sample is weighed into a 250 ml amber glass volumetric flask. 200 ml of the solvent are added from water / acetonitrile and the samples are placed in the ultrasonic bath for about 15 minutes. After cooling to room temperature, the sample solutions are adjusted to the mark with the solvent, filtered through a 0.22 ⁇ m PVDF filter into brown vials, discarding the first 2 ml, and subsequently injected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des granulés contenant une substance pharmaceutique qui présente une résistance à la rupture supérieure à 0,001 Newton, des procédés de fabrication de ces granulés, ainsi que des préparations pharmaceutiques à base de tels granulés.
EP08716523A 2007-03-13 2008-03-13 Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci Withdrawn EP2170288A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007012105A DE102007012105A1 (de) 2007-03-13 2007-03-13 Pellets enthaltend pharmazeutische Substanz, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP2008/002026 WO2008110374A2 (fr) 2007-03-13 2008-03-13 Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
EP2170288A2 true EP2170288A2 (fr) 2010-04-07

Family

ID=39496221

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08716523A Withdrawn EP2170288A2 (fr) 2007-03-13 2008-03-13 Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci

Country Status (5)

Country Link
US (1) US20100080849A1 (fr)
EP (1) EP2170288A2 (fr)
JP (1) JP2010520909A (fr)
DE (1) DE102007012105A1 (fr)
WO (1) WO2008110374A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432066A (zh) * 2013-07-23 2013-12-11 蚌埠丰原涂山制药有限公司 一种复方甘露醇注射液及其制备方法
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3721870A1 (fr) 2019-04-11 2020-10-14 ADD Advanced Drug Delivery Technologies, Ltd. Procédé de fabrication en continu d'un granulat de substance active
EP3721871A1 (fr) * 2019-04-11 2020-10-14 ADD Advanced Drug Delivery Technologies, Ltd. Procédé de fabrication en continu d'un granulat de substance active
WO2024088913A1 (fr) 2022-10-20 2024-05-02 Hermes Pharma Gmbh Revêtement d'ingrédient actif sans talc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661647A (en) * 1984-10-03 1987-04-28 Roquette Freres Directly compressible granular mannitol and method for its manufacture
WO1999004353A1 (fr) 1997-07-14 1999-01-28 Telefonaktiebolaget Lm Ericsson (Publ) Moyens de reception et de memorisation d'unites de transmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1275463A (fr) * 1960-09-28 1961-11-10 Potasse & Engrais Chimiques Perfectionnements à la granulation et au séchage de produits fluides
CA2363916C (fr) * 1998-12-23 2010-12-07 Aventis Behring Gmbh Granule adhesif de fibrine et procede de preparation dudit granule
US7572769B2 (en) * 1998-12-23 2009-08-11 Csl Behring Gmbh Fibrin adhesive granulate and method for its preparation
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US6716453B1 (en) * 1999-05-20 2004-04-06 Verion, Inc. Method for increasing the active loading of compressible composition forms
DE10322062A1 (de) 2003-05-15 2004-12-02 Glatt Ingenieurtechnik Gmbh Verfahren und Vorrichtung zum Aufbringen von Flüssigkeiten in eine Feststoffströmung eines Strahlschichtapparates
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004022102A1 (de) * 2004-05-05 2005-11-24 Glatt Ingenieurtechnik Gmbh Verfahren zur Verkapselung flüchtiger, oxidationsempfindlicher Substanzen sowie von Duft- und Geschmacksstoffen in Granulatform
DE102005037630A1 (de) * 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661647A (en) * 1984-10-03 1987-04-28 Roquette Freres Directly compressible granular mannitol and method for its manufacture
WO1999004353A1 (fr) 1997-07-14 1999-01-28 Telefonaktiebolaget Lm Ericsson (Publ) Moyens de reception et de memorisation d'unites de transmission

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Bruchfestigkeit", 29 December 2007 (2007-12-29), pages 1 - 1, Retrieved from the Internet <URL:http://de.wikipedia.org/wiki/Bruchfestigkeit> [retrieved on 20090506] *
HAUSER, F: "Ueber die Abhängigkeit der Bruchfestigkeit fester disperser Systeme von der Temperatur", KOLLOID-ZEITSCHRIFT, vol. 13, no. 3, 22 June 1913 (1913-06-22), pages 148 - 151, XP001556118 *

Also Published As

Publication number Publication date
DE102007012105A1 (de) 2008-09-18
US20100080849A1 (en) 2010-04-01
WO2008110374A3 (fr) 2009-06-25
JP2010520909A (ja) 2010-06-17
WO2008110374A2 (fr) 2008-09-18

Similar Documents

Publication Publication Date Title
EP1915135B1 (fr) Procédé pour produire les particules sphériques à base de substances pharmaceutiques
DE60023483T2 (de) Verfahren zur sprühtrocknung und eine anlage dafür sowie teilchenförmiges material hergestellt durch das verfahren
EP2170288A2 (fr) Granulés contenant une substance pharmaceutique, procédés de fabrication et utilisation de ceux-ci
DE60008636T2 (de) Verfahren zur Granulierung von Teilchen
EP0800860B1 (fr) Procédé et installation pour l&#39;agglomération des products sensibles à l&#39;hydrolyse ou moyen de vapeur d&#39;eau
DE60204125T2 (de) Verfahren zur herstellung von metoprolol enthaltenden mikropartikeln
EP1912621B1 (fr) Composition pharmaceutique a teneur en indometacine et/ou en acemetacine
DE60130270T2 (de) Verfahren zur herstellung einer pharmazeutischen zubereitung mit 5-aminosalicylsäure zur verwendung bei der behandlung von colitis ulcerosa und morbus crohn
EP3952843A1 (fr) Procédé de production continue de granulés de principe actif
DE2851627A1 (de) Verfahren zur agglomeration pulverfoermiger feststoffe in einem waessrigen medium
US20140163109A1 (en) Taste-masked ibupropen granules
WO2005110373A1 (fr) Granulat rapidement soluble de bromhexine / hydrochlorure de bromhexine, procede de fabrication dudit granulat et son utilisation
EP4003307A2 (fr) Procédé et dispositif de fabrication de granulés de cannabinoïde solubles essentiellement dans un milieu aqueux
WO2020208202A1 (fr) Procédé de production continue de granulés de principe actif
DE60117952T2 (de) Verfahren zum Beschichten von Teilchen
EP2244696B1 (fr) Support sous forme de pastilles, leurs procédés de production et leur utilisation
WO2009152921A1 (fr) Combinaison de polyols directement compressible
EP1609848A1 (fr) Procédé de granulation d&#39;un extrait de malt
DE60312635T2 (de) Zusammensetzung in Form einer festen Dispersion enthaltend Itraconazol und ein hydrophilisches Polymer mit einer verbesserten Bioverfügbarkeit
DE60312636T3 (de) Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer
DE1175826B (de) Verfahren zur Herstellung von Arzneipraeparaten zur oralen Verabreichung
DE102009052337A1 (de) Verfahren zum Herstellen von Pellets sowie Pellets
DE19623410A1 (de) Verfahren und Vorrichtung zur Agglomeration von hydrolyseempfindlichen Stoffen mittels Wasserdampf

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091228

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100805

DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130430